How logically impossible patents block biosimilars

Deep patent portfolios help drugmakers block market entry by potential biosimilars, but many biologic patents logically cannot be valid barriers to competitive entry.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Chen, B. K., Yang, Y. T. & Bennett, C. L. Drugs 78, 1777–1781 (2018).

    Article  Google Scholar 

  2. 2.

    Biologic Patent Transparency Act, S.659 (2019).

  3. 3.

    Brennan, Z. Six lawsuits target AbbVie’s Humira and its patent thicket. Regulatory Focus (2 April 2019).

  4. 4.

    Metallizing Engineering Co. v. Kenyon Bearing & Auto Parts Co., 153 F.2d 516 (2d Cir. 1946).

  5. 5.

    21 USC § 372(d).

  6. 6.

    42 USC § 262(l).

  7. 7.

    Price, W. N. II & Rai, A. K. Science 348, 188–189 (2015).

    CAS  Article  Google Scholar 

  8. 8.

    Kapczynski, A. 59 UCLA L. Rev. 970 (2012).

  9. 9.

    Genentech files complaint against Pfizer regarding Herceptin. Big Molecule Watch (21 November 2017).

  10. 10.

    Overpatented, overpriced: special Humira edition. I-MAK (17 September 2018).

Download references


The authors thank B. Potter and B. Wright for research assistance. WNP’s work was supported by the Cook Fund at the University of Michigan Law School and the Novo Nordisk Foundation (NNF17SA0027784).

Author information



Corresponding author

Correspondence to W. Nicholson Price II.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Price, W.N., Rai, A.K. How logically impossible patents block biosimilars. Nat Biotechnol 37, 862–863 (2019).

Download citation

Further reading


Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing